"The first quarter of 2024 marks our first full quarter as a profitable, pure-play neuroscience company. During the quarter, we continued to advance our strategic priorities acros ...
Alkermes will release earnings for Q1 on May 1.Wall Street analysts expect Alkermes will report earnings per share of $0.577.Go here to follow ...
ALKS 2680 reports positive results in narcolepsy & idiopathic hypersomnia study. Statistically significant improvements in sleep latency were observed across all doses tested. Phase 2 study for ...
Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and ...
Alkermes reports positive Phase 1 results for ALKS-2680 in narcolepsy and idiopathic hypersomnia, with significant efficacy and manageable side effects. The company plans to proceed with a Phase 2 ...
Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback